Skip to content
10-Q

Quarterly Report

ArriVent BioPharma, Inc. AVBP

0001558370-25-007276

← back to feed
Filed
May 12, 2025 12:00 AM ET
Period of report

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding Q1 2025 · May 9, 2025 34.21M sh
Short Term Investments Q1 2025 · Mar 31, 2025 $126.21M
Short Term Investments Q1 2025 · Dec 31, 2024 $144.57M
Cash And Equivalents Q1 2025 · Mar 31, 2025 $49.87M
Cash And Equivalents Q1 2025 · Dec 31, 2024 $74.29M
Current Liabilities Q1 2025 · Mar 31, 2025 $12.95M
Current Liabilities Q1 2025 · Dec 31, 2024 $17.27M
Total Liabilities Q1 2025 · Mar 31, 2025 $12.95M
Total Liabilities Q1 2025 · Dec 31, 2024 $17.29M
Current Assets Q1 2025 · Mar 31, 2025 $185.79M
Current Assets Q1 2025 · Dec 31, 2024 $226.98M
Total Assets Q1 2025 · Mar 31, 2025 $215.5M
Total Assets Q1 2025 · Dec 31, 2024 $274.94M
Shares Diluted Q1 2025 · Mar 31, 2024 25.05M sh
Operating Cash Flow Q1 2025 · Mar 31, 2024 −$18.63M
Stockholders Equity Q1 2025 · Mar 31, 2024 $317.72M
Stockholders Equity Q1 2025 · Dec 31, 2023 −$153.19M
Eps Diluted Q1 2025 · Mar 31, 2024 −$0.70
Eps Basic Q1 2025 · Mar 31, 2024 −$0.70
Sga Expense Q1 2025 · Mar 31, 2024 $3.7M
Rd Expense Q1 2025 · Mar 31, 2024 $16.98M
Net Income Q1 2025 · Mar 31, 2024 −$17.42M
Operating Income Q1 2025 · Mar 31, 2024 −$20.67M